Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
about
Treatment of relapsed and refractory multiple myelomaInterpretation of cytogenetic results in multiple myeloma for clinical practiceRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsMany multiple myelomas: making more of the molecular mayhemCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsA phthalimide derivative that inhibits centrosomal clustering is effective on multiple myelomaResponse-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03."Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancerInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Genetic markers used for risk stratification in multiple myeloma.Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese populationImproving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLong-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Genomic stratification of multiple myeloma treated with novel agents.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Lenalidomide in multiple myeloma: Current status and future potential.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.
P2860
Q26749180-40C6B4D3-F006-40CF-B1FE-716A41D6CC07Q26777803-607319ED-F4D0-4C44-962D-3C9335DD8399Q26795594-44EA4CC7-CB8F-400D-B796-06215DD95DF5Q26852892-3F475135-6B74-40FE-9EFD-67654564F1E0Q28084683-2074A12A-7140-4DC8-9FB5-16CFDF9F0310Q28480621-7F460DEC-D0F3-4D91-9E0F-F4D7640CAA77Q30313340-E437AE21-4AB4-474C-AD23-1499D0EA849CQ30424188-395AE393-7F0C-4515-8F14-1F4E70E809C4Q30657752-37167C67-69A7-44F6-9C12-015E66712C53Q33401759-F287E045-BC8A-4234-915B-8EA985C041D5Q33403183-E5408BE4-5401-4464-A252-FB074D849923Q33404007-4631827D-CE8D-49C2-927B-6D945FD1FA08Q33411708-7EB12AC1-1C52-4D85-BAC1-042660AE89CBQ33414647-861039E1-CC11-4B4A-B4AA-3AA8D8FA0FB3Q33785935-6399CF20-54DE-4F5F-82B6-DB9F5EBFA6CAQ34515117-8039BB88-70C1-4B5E-8B70-F0327339E785Q35802414-08F49CBD-0B3A-4FDF-88E1-454B6CC127E8Q35910262-3A66DAEC-6403-4C26-B71F-20F65789F66EQ36115674-1FE26A99-AB77-4710-B5CF-F489429AE8A7Q36473629-509758F7-BC53-4D60-9FBD-E54482624203Q36595290-AA58C534-EA7D-405B-9040-927765A8B0D7Q36907272-D3ED334A-71EF-4487-9AAC-7BF7F2AFED8DQ37037265-759ECAE6-8BD8-4512-B9FB-CB42284410F0Q37096649-AB962DCF-4A47-4367-AAAB-3418CFBA79E6Q37171994-99BDBFB2-F6F2-4F3F-B41A-9FD420A6A80EQ37228026-2E315EDB-BE97-4496-9158-F8538E12640EQ37228327-2C9639F4-1A3A-49B4-A45A-C51307BF4A27Q37397995-5CDAE8EF-99BF-4554-9D0E-02ED0E90A684Q37584754-A87901F5-9FBD-419F-83EF-A3F56AF42B10Q37835572-66F33BE5-4ACC-4B0D-AA64-3200A32A8B6DQ37835695-8B39A930-A77E-4804-8D9F-6864E1EAEDB1Q37851944-977E4B8C-B5BD-49C2-8DAA-22A5AFFEB3F7Q37858523-510EC154-23FF-475A-9C62-B0672712DD86Q37862262-4803D7FF-8C5F-45B4-B789-8806F72BDC15Q37913346-34DC90E9-24E7-49AC-AC54-B29E8F5A773AQ37949201-2BC88ADB-D4A6-4C29-8DA8-5F30BB3CA34DQ38013995-41681FFA-CFFF-43F9-BB40-2AEA98F104D6Q38031989-4460749C-8408-4121-9C3C-79AE67F38012Q38037600-7C0CD37C-59F8-40BF-91F7-CFCAA76DA7CBQ38108391-08E2BE4B-2EF8-4510-A343-0DEB109B5A77
P2860
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@en
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@nl
type
label
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@en
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@nl
prefLabel
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@en
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@nl
P2093
P2860
P356
P1433
P1476
Impact of high-risk cytogeneti ...... nalidomide plus dexaméthasone.
@en
P2093
H Avet-Loiseau
I Yakoub-Agha
IFM and MAG groups
J-P Fermand
L Garderet
P2860
P2888
P304
P356
10.1038/LEU.2009.273
P577
2010-01-14T00:00:00Z
P5875
P6179
1015330896